The shares of the prominent pharmaceutical company gained up to 14 percent in today’s trading session after the company’s net profits and revenue increased by 87 percent QoQ and 25 percent YoY, respectively, in Q4.
With a market capitalization of Rs 22,171.25 crore, the shares of AstraZeneca Pharma India Ltd were trading at Rs 8,868.50 per share, increasing around 11.29 percent as compared to the previous closing price of Rs 7,965.20 apiece.
Q4 Highlights
The shares of AstraZeneca Pharma India Ltd have seen positive movement after reporting positive Q4 results, revenue increased by 9 percent on a quarter-on-quarter basis from Rs 440 crore in Q3FY25 to Rs 480 crore in Q4FY25. Further, revenue increased by 25 percent year on year, from Rs 383 crore in Q4FY24 to Rs 480 crore in Q4FY25.
The company’s net profit increased by 87 percent on a quarter-on-quarter basis, from Rs.31 crore in Q3FY25 to Rs 58 crore in Q4FY25. Further, net profit magnified significantly by 48 percent year on year from Rs 39 crore in Q4FY24 to Rs 58 crore in Q4FY25.
The company posted a mixed FY24- 25 performance, with revenue magnified 32 percent from Rs 1,296 crore to Rs 1,716 crore. Net profit declined 28 percent, from Rs 162 crore to Rs 116 crore, reflecting weak profitability over the previous financial year. The board has approved a dividend of Rs. 32 per equity share of Rs. 2 each.
Dr. Sanjeev Panchal, Country President & Managing Director of the Company, said, “Our company delivered a strong growth in Financial Year 2024-25 by bringing innovative medicine launches in India, giving us momentum into 2025 and beyond. We are pleased to share that our company has, for the first time, crossed the Rs 1700 cr mark ($200 Mn). Science is sustaining and growing the success of our company, helping us transform the future of healthcare, and the health of people, society, and the planet.
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal, and metabolic; oncology, and respiratory diseases. The Company operates through the Healthcare segment.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
